Fidelity Investments’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $593M | Buy |
15,840,219
+80,420
| +0.5% | +$2.99M | 0.03% | 492 |
|
|
2026
Q1 | $572M | Buy |
15,759,799
+1,466,024
| +10% | +$65.5M | 0.03% | 464 |
|
|
2025
Q4 | $665M | Buy |
14,293,775
+106,277
| +0.7% | +$4.73M | 0.03% | 409 |
|
|
2025
Q3 | $591M | Buy |
14,187,498
+61,499
| +0.4% | +$1.97M | 0.03% | 436 |
|
|
2025
Q2 | $406M | Buy |
14,125,999
+94,730
| +0.7% | +$2.93M | 0.02% | 570 |
|
|
2025
Q1 | $471M | Buy |
14,031,269
+5,103,183
| +57% | +$191M | 0.03% | 478 |
|
|
2024
Q4 | $456M | Buy |
8,928,086
+4,472,316
| +100% | +$250M | 0.03% | 507 |
|
|
2024
Q3 | $228M | Buy |
4,455,770
+358,975
| +9% | +$18.5M | 0.01% | 784 |
|
|
2024
Q2 | $183M | Sell |
4,096,795
-366,881
| -8% | -$16.9M | 0.01% | 812 |
|
|
2024
Q1 | $209M | Buy |
4,463,676
+419,811
| +10% | +$16.4M | 0.01% | 770 |
|
|
2023
Q4 | $144M | Buy |
4,043,865
+1,903,004
| +89% | +$58.4M | 0.01% | 878 |
|
|
2023
Q3 | $63.7M | Buy |
2,140,861
+1,057,947
| +98% | +$21.8M | 0.01% | 1161 |
|
|
2023
Q2 | $19.5M | Buy |
1,082,914
+161,956
| +18% | +$3.23M | ﹤0.01% | 1646 |
|
|
2023
Q1 | $14.8M | Sell |
920,958
-962,160
| -51% | -$17.8M | ﹤0.01% | 1736 |
|
|
2022
Q4 | $34.5M | Sell |
1,883,118
-798,485
| -30% | -$14.1M | ﹤0.01% | 1404 |
|
|
2022
Q3 | $52.7M | Sell |
2,681,603
-305,417
| -10% | -$6.23M | 0.01% | 1228 |
|
|
2022
Q2 | $55.7M | Sell |
2,987,020
-350,375
| -10% | -$6.99M | 0.01% | 1209 |
|
|
2022
Q1 | $73.3M | Sell |
3,337,395
-384,900
| -10% | -$7.79M | 0.01% | 1219 |
|
|
2021
Q4 | $106M | Sell |
3,722,295
-704,139
| -16% | -$17.4M | 0.01% | 1078 |
|
|
2021
Q3 | $93.2M | Sell |
4,426,434
-692,514
| -14% | -$14.5M | 0.01% | 1130 |
|
|
2021
Q2 | $96.5M | Buy |
5,118,948
+180,632
| +4% | +$3.17M | 0.01% | 1134 |
|
|
2021
Q1 | $75.5M | Sell |
4,938,316
-33
| -0% | -$511 | 0.01% | 1200 |
|
|
2020
Q4 | $69.7M | Buy |
4,938,349
+5,833
| +0.1% | +$81.2K | 0.01% | 1189 |
|
|
2020
Q3 | $77.3M | Buy |
4,932,516
+5,681
| +0.1% | +$86.8K | 0.01% | 1036 |
|
|
2020
Q2 | $86.3M | Buy |
4,926,835
+1,488,535
| +43% | +$25.4M | 0.01% | 932 |
|
|
2020
Q1 | $50.5M | Sell |
3,438,300
-195,031
| -5% | -$4M | 0.01% | 1025 |
|
|
2019
Q4 | $91.2M | Buy |
3,633,331
+7,320
| +0.2% | +$139K | 0.01% | 946 |
|
|
2019
Q3 | $54.5M | Buy |
3,626,011
+5,310
| +0.1% | +$103K | 0.01% | 1130 |
|
|
2019
Q2 | $90.5M | Buy |
3,620,701
+6,413
| +0.2% | +$159K | 0.01% | 955 |
|
|
2019
Q1 | $82.3M | Buy |
3,614,288
+675,749
| +23% | +$16.6M | 0.01% | 985 |
|
|
2018
Q4 | $88.1M | Buy |
2,938,539
+220,701
| +8% | +$6.21M | 0.01% | 909 |
|
|
2018
Q3 | $77.9M | Buy |
+2,717,838
| New | +$80.7M | 0.01% | 1058 |
|
Other funds holding CRNX
FCM
DCM
JT
Fidelity Investments's CRNX Position: Q2 2026 in Review
Fidelity Investments increased its Crinetics Pharmaceuticals (CRNX) stake by 0.51% in Q2 2026, buying an estimated $2.99M and bringing the position to 15,840,219 shares worth $593M. The position accounts for 0.03% of the portfolio, ranked #492.
Fidelity Investments first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $665M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Fidelity Investments held 15,840,219 shares of Crinetics Pharmaceuticals worth $593M as of Q2 2026.
- Fidelity Investments bought 80,420 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.99M.
- Crinetics Pharmaceuticals made up 0.03% of Fidelity Investments's portfolio in Q2 2026, its #492 holding.
- Fidelity Investments first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Fidelity Investments's Crinetics Pharmaceuticals position peaked at $665M in Q4 2025.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.